ID: ALA375870

Max Phase: Preclinical

Molecular Formula: C17H11BrN2O2

Molecular Weight: 355.19

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1c(O)c(C2=Nc3ccccc3C2=O)c2cccc(Br)c21

Standard InChI:  InChI=1S/C17H11BrN2O2/c1-20-15-10(6-4-7-11(15)18)13(17(20)22)14-16(21)9-5-2-3-8-12(9)19-14/h2-8,22H,1H3

Standard InChI Key:  JIMBVEMVHPOOIA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 355.19

Molecular Weight (Monoisotopic): 354.0004

AlogP: 3.96

#Rotatable Bonds: 1

Polar Surface Area: 54.59

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.56

CX Basic pKa:

CX LogP: 4.31

CX LogD: 4.31

Aromatic Rings: 3

Heavy Atoms: 22

QED Weighted: 0.72

Np Likeness Score: 0.08

References

1. Ferandin Y, Bettayeb K, Kritsanida M, Lozach O, Polychronopoulos P, Magiatis P, Skaltsounis AL, Meijer L..  (2006)  3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.,  49  (15): [PMID:16854069] [10.1021/jm060314i]

2. Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soundararajan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL..  (2013)  Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.,  4  (1): [PMID:23336033] [10.1021/ml300207a]

Source

Source(1):

• Scientific Literature